Hypertensive disorders of pregnancy: preventative-, immediate- and long-term management

References

• The National Institute for Clinical Excellence, Scottish Executive Health Department and Department of Health Social Services and Public Safety Northern Ireland. Why Mothers Die – Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 2000–2002. TSO, London, UK (2003).
   Google Scholar
• Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PFA. WHO analysis of causes of maternal death: a systematic review. Lancet367(9516), 1066–1074 (2006).
   PubMed Web of Science ®Google Scholar
• Sibai BM. Treatment of hypertension in pregnant women. N. Engl. J. Med.335(4), 257–265 (1996).
   PubMed Web of Science ®Google Scholar
• Walters BN, Thompson ME, Lee A, De Swiet M. Blood pressure in the puerperium. Clin. Sci. (Lond.)71(5), 589–594 (1986).
   PubMed Web of Science ®Google Scholar
• Shennan A, Gupta M, Halligan A, Taylor DJ, De Swiet M. Lack of reproducibility in pregnancy of Korotkoff phase IV as measured by mercury sphygmomanometry. Lancet347(8995), 139–142 (1996).
   PubMed Web of Science ®Google Scholar
• Brown MA, Reiter L, Smith B, Buddle ML, Morris R, Whitworth JA. Measuring blood pressure in pregnant women: a comparison of direct and indirect methods. Am. J. Obstet. Gynecol.171(3), 661–667 (1994).
   PubMed Web of Science ®Google Scholar
• Natarajan P, Shennan AH, Penny J, Halligan AW, De Swiet M, Anthony J. Comparison of auscultatory and oscillometric automated blood pressure monitors in the setting of preeclampsia. Am. J. Obstet. Gynecol.181(5 Pt 1), 1203–1210 (1999).
   PubMed Web of Science ®Google Scholar
• Penny JA, Shennan AH, Halligan AW, Taylor DJ, De Swiet M, Anthony J. Blood pressure measurement in severe pre-eclampsia. Lancet349(9064), 1518 (1997).
   PubMed Web of Science ®Google Scholar
• Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am. J. Obstet. Gynecol.158(4), 892–898 (1988).
   PubMed Web of Science ®Google Scholar
• Martin JN Jr, Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet. Gynecol.105(2), 246–254 (2005).
   PubMed Web of Science ®Google Scholar
• Lindenstrom E, Boysen G, Nyboe J. Influence of systolic and diastolic blood pressure on stroke risk: a prospective observational study. Am. J. Epidemiol.142(12), 1279–1290 (1995).
   PubMed Web of Science ®Google Scholar
• Magee LA, Ornstein MP, von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. Br. Med. J.318(7194), 1332–1336 (1999).
   PubMed Web of Science ®Google Scholar
• Brown MA, Hague WM, Higgins J et al. The detection, investigation and management of hypertension in pregnancy: full consensus statement. Aust. NZ J. Obstet. Gynaecol.40(2), 139–155 (2000).
   PubMed Web of Science ®Google Scholar
• Sibai BM, Akl S, Fairlie F, Moretti M. A protocol for managing severe preeclampsia in the second trimester. Am. J. Obstet. Gynecol.163(3), 733–738 (1990).
   PubMed Web of Science ®Google Scholar
• Sibai BM. Diagnosis and management of chronic hypertension in pregnancy. Obstet. Gynecol.78(3 Pt 1), 451–461 (1991).
   PubMed Web of Science ®Google Scholar
• McCowan LM, Buist RG, North RA, Gamble G. Perinatal morbidity in chronic hypertension. Br. J. Obstet. Gynaecol.103(2), 123–129 (1996).
   PubMedGoogle Scholar
• Walker JJ. Pre-eclampsia. Lancet356(9237), 1260–1265 (2000).
   PubMed Web of Science ®Google Scholar
• Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet365(9461), 785–799 (2005).
   PubMed Web of Science ®Google Scholar
• Pipkin FB. Risk factors for preeclampsia. N. Engl. J. Med.344(12), 925–926 (2001).
   PubMed Web of Science ®Google Scholar
• Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. Br. Med. J.330(7491), 565 (2005).
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science308(5728), 1592–1594 (2005).
   PubMed Web of Science ®Google Scholar
• Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am. J. Obstet. Gynecol.180(2 Pt 1), 499–506 (1999).
   PubMed Web of Science ®Google Scholar
• Ramsay JE, Ferrell WR, Crawford L, Wallace AM, Greer IA, Sattar N. Divergent metabolic and vascular phenotypes in pre-eclampsia and intrauterine growth restriction: relevance of adiposity. J. Hypertens.22(11), 2177–2183 (2004).
   PubMed Web of Science ®Google Scholar
• Ramsay JE, Stewart F, Greer IA, Sattar N. Microvascular dysfunction: a link between pre-eclampsia and maternal coronary heart disease. BJOG110(11), 1029–1031 (2003).
   PubMed Web of Science ®Google Scholar
• Solomon CG, Seely EW. Hypertension in pregnancy. Endocrinol. Metab. Clin. North Am.35(1), 157–171, vii (2006).
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest.111(5), 649–658 (2003).
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med.350(7), 672–683 (2004).
   PubMed Web of Science ®Google Scholar
• Thadhani R, Ecker JL, Mutter WP et al. Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. Hypertension43(5), 988–992 (2004).
   Google Scholar
• Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension46(5), 1077–1085 (2005).
   PubMed Web of Science ®Google Scholar
• Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet. Gynecol.104(6), 1367–1391 (2004).
   PubMed Web of Science ®Google Scholar
• Tjoa ML, Oudejans CB, van Vugt JM, Blankenstein MA, van Wijk IJ. Markers for presymptomatic prediction of preeclampsia and intrauterine growth restriction. Hypertens. Pregnancy23(2), 171–189 (2004).
   PubMed Web of Science ®Google Scholar
• Chien PF, Arnott N, Gordon A, Owen P, Khan KS. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. Br. J. Obstet. Gynecol.107(2), 196–208 (2000).
   Google Scholar
• Yu CK, Papageorghiou AT, Parra M, Palma DR, Nicolaides KH. Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks’ gestation. Ultrasound Obstet. Gynecol.22(3), 233–239 (2003).
   PubMed Web of Science ®Google Scholar
• Yu CK, Papageorghiou AT, Boli A, Cacho AM, Nicolaides KH. Screening for pre-eclampsia and fetal growth restriction in twin pregnancies at 23 weeks of gestation by transvaginal uterine artery Doppler. Ultrasound Obstet. Gynecol.20(6), 535–540 (2002).
   PubMed Web of Science ®Google Scholar
• Spencer K, Yu CK, Savvidou M, Papageorghiou AT, Nicolaides KH. Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks’ gestation. Ultrasound Obstet. Gynecol.27(6), 658–663 (2006).
   PubMed Web of Science ®Google Scholar
• Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat. Diagn.25(10), 949–953 (2005).
   PubMed Web of Science ®Google Scholar
• Vainio M, Kujansuu E, Koivisto AM, Maenpaa J. Bilateral notching of uterine arteries at 12–14 weeks of gestation for prediction of hypertensive disorders of pregnancy. Acta Obstet. Gynecol. Scand.84(11), 1062–1067 (2005).
   PubMed Web of Science ®Google Scholar
• Nicolaides KH, Bindra R, Turan OM et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet. Gynecol.27(1), 13–17 (2006).
   PubMed Web of Science ®Google Scholar
• Yu CK, Smith GC, Papageorghiou AT, Cacho AM, Nicolaides KH. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am. J. Obstet. Gynecol.193(2), 429–436 (2005).
   PubMed Web of Science ®Google Scholar
• Papageorghiou AT, Yu CK, Erasmus IE, Cuckle HS, Nicolaides KH. Assessment of risk for the development of pre-eclampsia by maternal characteristics and uterine artery Doppler. Br. J. Obstet. Gynecol.112(6), 703–709 (2005).
   Google Scholar
• Ebrashy A, Ibrahim M, Marzook A, Yousef D. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14–16 weeks pregnancy: randomized controlled clinical trial. Croat. Med. J.46(5), 826–831 (2005).
   PubMed Web of Science ®Google Scholar
• Vainio M, Kujansuu E, Iso-Mustajarvi M, Maenpaa J. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. Br. J. Obstet. Gynecol.109(2), 161–167 (2002).
   Google Scholar
• Chiaffarino F, Parazzini F, Paladini D et al. A small randomised trial of low-dose aspirin in women at high risk of pre-eclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol.112(2), 142–144 (2004).
   PubMed Web of Science ®Google Scholar
• Duley L, Henderson-Smart D, Meher S. Altered dietary salt for preventing pre-eclampsia, and its complications. Cochrane Database Syst. Rev. (4), CD005548 (2005).
   Google Scholar
• Moutquin JM, Garner PR, Burrows RF et al. Report of the Canadian Hypertension Society Consensus Conference: 2. Nonpharmacologic management and prevention of hypertensive disorders in pregnancy. CMAJ157(7), 907–919 (1997).
   Google Scholar
• Villar J, Merialdi M, Gulmezoglu AM et al. Nutritional interventions during pregnancy for the prevention or treatment of maternal morbidity and preterm delivery: an overview of randomized controlled trials. J. Nutr.133(5 Suppl. 2), S1606–S1625 (2003).
   Google Scholar
• Atallah AN, Hofmeyr GJ, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst. Rev. (1), CD001059 (2002).
   Google Scholar
• Levine RJ, Hauth JC, Curet LB et al. Trial of calcium to prevent preeclampsia. N. Engl. J. Med.337(2), 69–76 (1997).
   PubMed Web of Science ®Google Scholar
• Duley L, Henderson-Smart DJ, Knight M, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev. (1), CD004659 (2004).
   Google Scholar
• Bonnar J, McNicol GP, Douglas AS. Coagulation and fibrinolytic systems in pre-eclampsia and eclampsia. Br. Med. J.2(752), 12–16 (1971).
   PubMed Web of Science ®Google Scholar
• Bonnar J, Redman CW, Denson KW. The role of coagulation and fibrinolysis in preeclampsia. Perspect. Nephrol. Hypertens.5, 85–93 (1976).
   PubMedGoogle Scholar
• Greer IA, Nelson-Piercy C. Low-molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood106(2), 401–407 (2005).
   PubMed Web of Science ®Google Scholar
• Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst. Rev. (2), CD002859 (2005).
   Google Scholar
• Lassere M, Empson M. Treatment of antiphospholipid syndrome in pregnancy – a systematic review of randomized therapeutic trials. Thrombosis Res.114(5–6), 419–426 (2004).
   PubMed Web of Science ®Google Scholar
• Stone S, Khamashta MA, Poston L. Placentation, antiphospholipid syndrome and pregnancy outcome. Lupus10(2), 67–74 (2001).
   PubMedGoogle Scholar
• Shehata HA, Nelson-Piercy C, Khamashta MA. Management of pregnancy in antiphospholipid syndrome. Rheum. Dis. Clin. North Am.27(3), 643–659 (2001).
   PubMedGoogle Scholar
• Beazley D, Ahokas R, Livingston J, Griggs M, Sibai BM. Vitamin C and E supplementation in women at high risk for preeclampsia: a double-blind, placebo-controlled trial. Am. J. Obstet. Gynecol.192(2), 520–521 (2005).
   PubMed Web of Science ®Google Scholar
• Poston L, Briley AL, Seed PT, Kelly FJ, Shennan A. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet8367(9517), 1145–1154 (2006).
   Google Scholar
• Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL. Antioxidant vitamin supplements and cardiovascular disease. Circulation110(5), 637–641 (2004).
   PubMed Web of Science ®Google Scholar
• Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med.142(1), 37–46 (2005).
   PubMed Web of Science ®Google Scholar
• Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS. Vitamins C and E and the risks of preeclampsia and perinatal complications. N. Engl. J. Med.354(17), 1796–1806 (2006).
   PubMed Web of Science ®Google Scholar
• Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst. Rev. (2), CD002252 (2001).
   Google Scholar
• Duley L, Henderson-Smart DJ. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst. Rev. (4), CD001449 (2002).
   Google Scholar
• von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet355(9198), 87–92 (2000).
   PubMed Web of Science ®Google Scholar
• Redman CW, Beilin LJ, Bonnar J. Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects. Br. J. Obstet. Gynaecol.84(6), 419–426 (1977).
   PubMedGoogle Scholar
• Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet1(8273), 647–649 (1982).
   PubMed Web of Science ®Google Scholar
• Rubin PC, Butters L, Clark DM et al. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet1(8322), 431–434 (1983).
   PubMed Web of Science ®Google Scholar
• Gallery ED, Ross MR, Gyory AZ. Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa. Br. Med. J. (Clin. Res. Edition)291(6495), 563–566 (1985).
   PubMedGoogle Scholar
• Pickles CJ, Symonds EM, Broughton PF. The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. Br. J. Obstet. Gynaecol.96(1), 38–43 (1989).
   PubMedGoogle Scholar
• Rubin PC, Butters L, Clark D et al. Obstetric aspects of the use in pregnancy-associated hypertension of the beta-adrenoceptor antagonist atenolol. Am. J. Obstet. Gynecol.150(4), 389–392 (1984).
   PubMedGoogle Scholar
• Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. Br. Med. J.301(6752), 587–589 (1990).
   PubMed Web of Science ®Google Scholar
• Sibai BM, Gonzalez AR, Mabie WC, Moretti M. A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet. Gynecol.70(3 Pt 1), 323–327 (1987).
   PubMed Web of Science ®Google Scholar
• Mabie WC, Gonzalez AR, Sibai BM, Amon E. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet. Gynecol.70(3 Pt 1), 328–333 (1987).
   PubMed Web of Science ®Google Scholar
• Reynolds B, Butters L, Evans J, Adams T, Rubin PC. First year of life after the use of atenolol in pregnancy associated hypertension. Arch. Dis. Child59(11), 1061–1063 (1984).
   PubMed Web of Science ®Google Scholar
• Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. Br. Med. J.327(7421), 955–960 (2003).
   PubMed Web of Science ®Google Scholar
• Constantine G, Beevers DG, Reynolds AL, Luesley DM. Nifedipine as a second line antihypertensive drug in pregnancy. Br. J. Obstet. Gynaecol.94(12), 1136–1142 (1987).
   PubMedGoogle Scholar
• Broughton PF, Lawrence MR. The effect of nitrendipine (NIT) on maternal and fetal blood pressure, uterine blood flow, and blood gas status in pregnant sheep. J. Cardiovasc. Pharmacol.12(Suppl. 6), S123–S125 (1988).
   Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation; a Reference Guide to Fetal and Neonatal Risk (6th Edition). Lipincott Williams and Wilkins, PA, USA (2002).
   Google Scholar
• Gallery ED, Hunyor SN, Gyory AZ. Plasma volume contraction: a significant factor in both pregnancy-associated hypertension (pre-eclampsia) and chronic hypertension in pregnancy. Q. J. Med.48(192), 593–602 (1979).
   PubMedGoogle Scholar
• Sibai BM, Grossman RA, Grossman HG. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am. J. Obstet. Gynecol.150(7), 831–835 (1984).
   PubMed Web of Science ®Google Scholar
• Zamorski MA, Green LA. NHBPEP report on high blood pressure in pregnancy: a summary for family physicians. Am. Fam. Physician64(2), 263–270, 216 (2001).
   PubMedGoogle Scholar
• Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am. J. Obstet. Gynecol.183(1), S1–S22 (2000).
   PubMed Web of Science ®Google Scholar
• Zoma WD, Baker RS, Friedman A, Clark KE. Sildenafil citrate (Viagra) increases uterine blood flow and potentiates estrogen-induced vasodilation. J. Soc. Gynecol. Invest.8(1) (2006) (Abstract 286A).
   Google Scholar
• Wareing M, Myers JE, O’Hara M, Baker PN. Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J. Clin. Endocrinol. Metab.90(5), 2550–2555 (2005).
   PubMed Web of Science ®Google Scholar
• Hoekstra RE, Ferrara TB, Couser RJ, Payne NR, Connett JE. Survival and long-term neurodevelopmental outcome of extremely premature infants born at 23–26 weeks’ gestational age at a tertiary center. Pediatrics113(1 Pt 1), E1–E6 (2004).
   Web of Science ®Google Scholar
• Burrows RF, Burrows EA. Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust. NZ J. Obstet. Gynaecol.38(3), 306–311 (1998).
   PubMed Web of Science ®Google Scholar
• Mann R, Mackay F, Pearce G, Freemantle S, Wilton L. Losartan: a study of pharmacovigilance data on 14,522 patients. J. Hum. Hypertens.13(8), 551–557 (1999).
   PubMed Web of Science ®Google Scholar
• Barr M Jr. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology50(6), 399–409 (1994).
   PubMedGoogle Scholar
• Saji H, Yamanaka M, Hagiwara A, Ijiri R. Losartan and fetal toxic effects. Lancet357(9253), 363 (2001).
   PubMed Web of Science ®Google Scholar
• Wilson BJ, Watson MS, Prescott GJ et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. Br. Med. J.326(7394), 845–849 (2003).
   PubMed Web of Science ®Google Scholar
• WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone C. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet348(9026), 505–510 (1996).
   PubMed Web of Science ®Google Scholar
• Hannaford P, Ferry S, Hirsch S. Cardiovascular sequelae of toxaemia of pregnancy. Heart77(2), 154–158 (1997).
   PubMed Web of Science ®Google Scholar
• Van Walraven C, Mamdani M, Cohn A, Katib Y, Walker M, Rodger MA. Risk of subsequent thromboembolism for patients with pre-eclampsia. Br. Med. J.326(7393), 791–792 (2003).
   PubMedGoogle Scholar
• Jonsdottir LS, Arngrimsson R, Geirsson RT, Sigvaldason H, Sigfusson N. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet. Gynecol. Scand.74(10), 772–776 (1995).
   PubMed Web of Science ®Google Scholar
• Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births. Lancet357(9273), 2002–2006 (2001).
   PubMed Web of Science ®Google Scholar
• Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? Br. Med. J.325(7356), 157–160 (2002).
   PubMed Web of Science ®Google Scholar
• Green A, Beral V, Moser K. Mortality in women in relation to their childbearing history. Br. Med. J.297(6645), 391–395 (1988).
   PubMedGoogle Scholar
• Ness RB, Harris T, Cobb J et al. Number of pregnancies and the subsequent risk of cardiovascular disease. N. Engl. J. Med.328(21), 1528–1533 (1993).
   PubMed Web of Science ®Google Scholar
• Dekker JM, Schouten EG. Number of pregnancies and risk of cardiovascular disease. N. Engl. J. Med.329(25), 1893–1894 (1993).
   PubMed Web of Science ®Google Scholar
• Lawlor DA, Emberson JR, Ebrahim S et al. Is the association between parity and coronary heart disease due to biological effects of pregnancy or adverse lifestyle risk factors associated with child-rearing? Findings from the British Women’s Heart and Health Study and the British Regional Heart Study. Circulation107(9), 1260–1264 (2003).
   PubMed Web of Science ®Google Scholar
• Iinuma H. Follow-up study on women suffered from severe toxemia of pregnancy. Nippon Sanka Fujinka Gakkai Zasshi40(8), 980–990 (1988).
   PubMedGoogle Scholar
• Freeman DJ, McManus F, Brown EA et al. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension44(5), 708–714 (2004).
   PubMed Web of Science ®Google Scholar
• Hubel CA, Powers RW, Snaedal S et al. C-reactive protein is increased 30 years after eclamptic pregnancy. J. Soc. Gynecol. Investig.13(2), (2006).
   Google Scholar
• Lampinen KH, Ronnback M, Kaaja RJ, Groop PH. Impaired vascular dilatation in women with a history of pre-eclampsia. J. Hypertens.24(4), 751–756 (2006).
   PubMed Web of Science ®Google Scholar
• Hooper L, Summerbell CD, Higgins JP et al. Dietary fat intake and prevention of cardiovascular disease: systematic review. Br. Med. J.322(7289), 757–763 (2001).
   PubMed Web of Science ®Google Scholar
• Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr. Probl. Cardiol.29(8), 439–493 (2004).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeifer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation100(3), 230–235 (1999).
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: The PRavastatin INflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. J. Am. Med. Assoc.286(1), 64–70 (2001).
   Google Scholar
• Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA285(19), 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Mora S, Ridker PM. Justification for the Use of statins in primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Am. J. Cardiol.97(2 Suppl. 1), 33–41 (2006).
   PubMed Web of Science ®Google Scholar
• Roessler E, Muenke M. How a Hedgehog might see holoprosencephaly. Hum. Mol. Genet. 12 Spec. No. 1, R15–R25 (2003).
   Google Scholar
• McMahon AP, Ingham PW, Tabin CJ. Developmental roles and clinical significance of hedgehog signaling. Curr. Top. Dev. Biol.53, 1–114 (2003).
   PubMed Web of Science ®Google Scholar
• Cooper MK, Wassif CA, Krakowiak PA et al. A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat. Genet.33(4), 508–513 (2003).
   PubMed Web of Science ®Google Scholar
• Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin. Pharmacokinet.31(5), 348–371 (1996).
   PubMed Web of Science ®Google Scholar
• Gofflot F, Hars C, Illien F et al. Molecular mechanisms underlying limb anomalies associated with cholesterol deficiency during gestation: implications of Hedgehog signaling. Hum. Mol. Genet.12(10), 1187–1198 (2003).
   PubMed Web of Science ®Google Scholar
• Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am. J. Med. Genet. A.131(3), 287–298 (2004).
   PubMed Web of Science ®Google Scholar
• Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N. Engl. J. Med.350(15), 1579–1582 (2004).
   PubMed Web of Science ®Google Scholar
• Brousseau ME, Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med.350(15), 1505–1515 (2004).
   Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J. Am. Med. Assoc.291(9), 1071–1080 (2004).
   Google Scholar
• Altmann SW, Davis J, Zhu LJ et al. Niemann-Pick C1 Like 1 protein is critical for Intestinal cholesterol absorption. Science303(5661), 1201–1204 (2004).
   PubMed Web of Science ®Google Scholar